Deletion of Bemarituzumab

Comment: I couldn't find any mention in PubMed, which is a red flag. However there are press releases available so I added one (Business Wire) to the article. I also added a short description from the National Cancer Institute. I looked for a specific drugs notability guideline in Wikipedia, at ,  and , but we don't seem to have one. In particular, I could find no mention of Phase II or III drugs being inherently notable. I am reluctant to delete because I think that bemarituzumab is likely to become notable in the next couple of years. Nevertheless, I acknowledge that the drug does not currently meet Wikipedia's general notability guideline standard
Stance: delete
Cited policy: Wikipedia:Notability (WP:N||WP:SNG||WP:PHARM)

Comment: this appears to be , especially if "As of 2010, about 50% of drug candidates either fail during the Phase III trial or are rejected by the national regulatory agency" (from Phases of clinical research#Phase III) is still correct
Stance: delete
Cited policy: Wikipedia:Too soon (WP:TOOSOON)